Federal traction BRT recently secured its first federal contract with the EPA for mouse assays to assess lead bioavailability in soil and dust, signaling the potential to expand government-focused immunotoxicology and environmental exposure studies.

NAMs expansion The company offers in vitro sensitization and hypersensitivity testing using NAMs such as DPRA, KeratinoSens, h-CLAT, and GARD, presenting a ready-made pathway to partner with biotech and chemical firms seeking alternative methods and faster development timelines.

Niche leadership As an early U.S. provider of the GARD test method and a focus on human-relevant models, BRT can position itself to win partnerships with pharma, biotech, and government entities pursuing cutting-edge immunotoxicology data.

SMB to mid-market With 11-50 employees and revenue in the mid single to low double digits, BRT is well-suited to target medium-sized biotech and specialty chemical companies needing specialized preclinical safety data without engaging large CROs.

Full-spectrum capabilities Leveraging both in vivo and in vitro immune function assessments, infectious disease models, and a broad immunoassay suite, BRT can cross-sell integrated immunotoxicology packages to current and prospective clients across biotech, pharma, and government sectors.